2.4 Diagnostic Laboratory and Imaging Interpretation

2.4 Diagnostic Laboratory and Imaging Interpretation

Core Concept: While psychiatric diagnoses are primarily clinical, laboratory tests and neuroimaging are indispensable for ruling out organic etiologies, establishing baseline metabolic health, and conducting therapeutic drug monitoring. The PMHNP must interpret these diagnostics accurately to ensure patient safety.

Foundational Laboratory Screening

Before diagnosing a primary psychiatric disorder, the PMHNP must exclude medical conditions that mimic psychiatric symptoms. A standard baseline panel typically includes:

• Complete Blood Count (CBC):
  • Anemia (low Hgb/Hct) can cause fatigue and apathy, mimicking depression.
  • Leukocytosis (elevated WBC) suggests infection (e.g., UTI causing delirium in older adults).
  • Macrocytosis (elevated MCV) may indicate B12/folate deficiency or chronic alcohol use.
• Comprehensive Metabolic Panel (CMP):
  • Electrolytes: Hyponatremia (can cause confusion, seizures) is a known side effect of SSRIs/SNRIs and oxcarbazepine.
  • Renal Function (BUN/Creatinine): Essential before starting renally cleared psychotropics (like lithium or gabapentin).
  • Hepatic Function (AST/ALT/Bilirubin): Hepatic encephalopathy can present with severe agitation or psychosis. Baseline LFTs are required before starting hepatically metabolized drugs (like Depakote or duloxetine).
• Thyroid Function (TSH / Free T4):
  • Hyperthyroidism: Low TSH, High T4. Mimics anxiety, mania, or panic attacks.
  • Hypothyroidism: High TSH, Low T4. Mimics depression, fatigue, and cognitive slowing.
• Vitamin B12 and Folate: Deficiencies can cause depression, cognitive decline (dementia), and peripheral neuropathy.
• Urinalysis (UA): Especially in the elderly, a simple UTI is a leading cause of sudden-onset delirium or behavioral changes.

Specialized Baseline Tests

• Fasting Lipid Panel and HbA1c: Required before starting any second-generation antipsychotic due to metabolic syndrome risk (highest with clozapine and olanzapine).
• Prolactin Level: Baseline before antipsychotics, especially risperidone or paliperidone (highest D2 antagonism of tuberoinfundibular pathway).
• Pregnancy Test (hCG): Mandatory for any person of childbearing potential before initiating lithium, valproate, carbamazepine, or teratogenic antidepressants.
• RPR/VDRL: Considered in patients with new-onset psychosis, cognitive decline, or high-risk sexual history to rule out neurosyphilis.
• HIV Testing: Recommended in patients with new-onset psychosis or cognitive decline.

Therapeutic Drug Monitoring (TDM)

Several psychotropics have narrow therapeutic indices and require routine blood level monitoring to ensure efficacy and prevent toxicity.

Lithium

• Therapeutic Range: 0.6 - 1.2 mEq/L (maintenance is often 0.6 - 0.8; acute mania up to 1.2).
• Toxicity: Can occur > 1.5 mEq/L. Symptoms include coarse tremor, ataxia, confusion, nausea, vomiting, and eventually seizures or coma.
• Monitoring Required: Lithium is entirely renally cleared and can cause thyroid dysfunction. Regular monitoring of BUN, Creatinine, and TSH is mandatory.
• Drug Interactions: NSAIDs, ACE inhibitors, ARBs, and thiazide diuretics reduce lithium clearance and increase toxicity risk.
• Hemodialysis Indications: Serum level >2.5 mEq/L with severe symptoms, or >4.0 mEq/L regardless of symptoms.

Valproic Acid (Depakote)

• Therapeutic Range: 50 - 125 mcg/mL for mania.
• Toxicity Risk: Hepatotoxicity and pancreatitis. Monitor LFTs and platelets (can cause thrombocytopenia).
• Hyperammonemic Encephalopathy: Can occur even with normal LFTs; check ammonia if patient becomes confused. Treat with L-carnitine.

Carbamazepine (Tegretol)

• Therapeutic Range: 4 - 12 mcg/mL.
• Toxicity Risk: Agranulocytosis, aplastic anemia, and hyponatremia. Monitor CBC and CMP.
• Auto-Induction: Carbamazepine induces its own metabolism via CYP3A4; half-life shortens after 2-4 weeks, requiring dose adjustment.
• HLA-B*1502 Testing: Required in patients of Asian descent prior to initiation due to high risk of Stevens-Johnson Syndrome.

Clozapine

• While we don't strictly monitor 'levels' for efficacy in the same way, we strictly monitor the Absolute Neutrophil Count (ANC) due to the risk of severe neutropenia/agranulocytosis. ANC must be monitored via the REMS program.
• REMS Thresholds (General Population): Baseline ANC must be >=1,500/microL. Weekly monitoring for 6 months, then biweekly for 6 months, then monthly. Hold if ANC <1,000/microL.
• Benign Ethnic Neutropenia (BEN): Baseline ANC >=1,000/microL acceptable; threshold for holding is <500/microL.

Urine Drug Screens (UDS)

UDS are critical for assessing substance use, but PMHNPs must be acutely aware of their limitations, particularly false positives.

Standard UDS tests use immunoassays, which cross-react with structurally similar molecules.

• Amphetamines: False positives from bupropion, pseudoephedrine, trazodone.
• PCP (Phencyclidine): False positives from venlafaxine (Effexor), dextromethorphan, diphenhydramine.
• Opioids: Standard screens often miss synthetic opioids (like fentanyl or methadone) which require specific expanded panels. False positives from poppy seeds.
• Cannabis (THC): Can remain positive for weeks in heavy, chronic users due to fat storage.

Clinical Pearl: A positive immunoassay screen is presumptive. If the result is contested or carries significant legal/clinical weight, it MUST be confirmed by Gas Chromatography-Mass Spectrometry (GC-MS), which is highly specific.

Common False Positive Reference Table

Electrocardiogram (EKG) Monitoring

QTc prolongation is a critical cardiac adverse effect of many psychotropics. The PMHNP must understand thresholds and high-risk agents.

• Normal QTc: <440 ms (men), <460 ms (women).
• Prolonged: >470 ms (men), >480 ms (women).
• Critical Risk: >500 ms or increase >60 ms from baseline - requires dose reduction or discontinuation.
• High-Risk Agents: Thioridazine (highest), IV haloperidol, ziprasidone, pimozide, citalopram (FDA max 40 mg/day; 20 mg/day in elderly/CYP2C19 poor metabolizers), TCAs, methadone.
• TCA Overdose: Causes QRS widening (>100 ms predicts seizures; >160 ms predicts arrhythmias). Treat with IV sodium bicarbonate.

Neuroimaging Indications

Psychiatric diagnoses do not routinely require imaging. However, structural imaging (CT or MRI of the head) is indicated in the presence of 'red flag' symptoms:

1. First-episode psychosis: Especially in older adults or atypical presentations, to rule out tumors, strokes, or demyelinating disease.
2. New-onset cognitive decline: To assess for dementia patterns, hydrocephalus, or cerebrovascular disease.
3. Psychiatric symptoms accompanied by focal neurological deficits: (e.g., depression with new-onset left-sided weakness).
4. Sudden, unexplained personality changes: Particularly if age > 40.
5. History of significant traumatic brain injury (TBI).

MRI is preferred for structural detail (soft tissue, demyelination), while CT is faster and preferred in emergencies (acute hemorrhage, large tumors). PET/SPECT imaging assesses regional cerebral metabolism and is primarily used in research or specialized dementia workups (e.g., parietotemporal hypometabolism in Alzheimer's disease).